surmount 1 tirzepatide trials SURMOUNT-1 Trial Overview of key tirzepatide clinical – Tirzepatide delivers substantial, sustained reductions

Risk Profile: This endogenous stimulation is typically considered lower-risk than direct GH injections, as it minimizes the risk of completely shutting down the bodys natural production and avoids many of the side effects associated with high-level synthetic hormone replacement

The public comment period on the proposal closes June 29-30, 2026

Alternatively, you can: Call the member services phone number on the back of your Aetna member ID card or contact Aetna by using live chat or email

We handle the entire prior authorization process on your behalf, which means you can focus entirely on achieving your weight loss goals with minimal financial stress